Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nilotinib

FDA-approved product (tablet, orally disintegrating, oral), marketed as Cavhanza, Nilotinib D-Tartrate, Nilotinib Hydrochloride and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nilotinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Chronic myelogenous leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nilotinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nilotinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

    NCT05286528 · start 2020-11-18

    Registered record
    Registry ID
    NCT05286528
    Conditions
    Chronic Myeloid Leukaemia
    Interventions
    Bosutinib; Imatinib; Nilotinib; Dasatinib; Ponatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-18
    Completion
    2022-01-31
    Enrolment
    1,484

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukaemia
    InterventionBosutinib; Imatinib; Nilotinib; Dasatinib +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

    NCT04006847 · start 2020-09-14

    Registered record
    Registry ID
    NCT04006847
    Conditions
    Chronic Myeloid Leukemia, Chronic Phase
    Interventions
    Eicosapentaenoic Acid; Tyrosine kinase inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-09-14
    Completion
    2021-05-21
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia, Chronic Phase
    InterventionEicosapentaenoic Acid; Tyrosine kinase inhibitor
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

    NCT04326933 · start 2020-01-01

    Registered record
    Registry ID
    NCT04326933
    Conditions
    Patients Diagnosed as Chronic Meyloid Leukemia
    Interventions
    Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2022-03-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Diagnosed as Chronic Meyloid Leukemia
    InterventionTyrosine kinase Inhibitors (Imatinib & Nilotinib)
    PhaseNot recorded
    Registry statusUnknown

  • Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

    NCT04002674 · start 2019-07-01

    Registered record
    Registry ID
    NCT04002674
    Conditions
    Dementia With Lewy Bodies
    Interventions
    Placebo oral capsule; Nilotinib Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2025-04-30
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia With Lewy Bodies
    InterventionPlacebo oral capsule; Nilotinib Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

    NCT03578367 · start 2018-11-22

    Registered record
    Registry ID
    NCT03578367
    Conditions
    CML; Chronic Myelogenous Leukemia; Leukemia, Myeloid Chronic; Hematologic Diseases
    Interventions
    Asciminib add-on; Imatinib; Nilotinib; Asciminib 80mg QD (asciminib single agent (ASAC))
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-22
    Completion
    2025-02-26
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCML; Chronic Myelogenous Leukemia; Leukemia, Myeloid Chronic; Hematologic Diseases
    InterventionAsciminib add-on; Imatinib; Nilotinib; Asciminib 80mg QD (asciminib single agent (ASAC))
    PhasePhase 2
    Registry statusCompleted

  • Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

    NCT03654768 · start 2018-10-24

    Registered record
    Registry ID
    NCT03654768
    Conditions
    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions
    Bosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib; Ruxolitinib; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-10-24
    Completion
    2028-07-01
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    InterventionBosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia

    NCT03214718 · start 2017-08-05

    Registered record
    Registry ID
    NCT03214718
    Conditions
    Chronic Myeloid Leukemia Patients
    Interventions
    Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day; Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-08-05
    Completion
    2019-08-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia Patients
    InterventionMeasurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day; Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day
    PhaseNot applicable
    Registry statusUnknown

  • Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

    NCT02954978 · start 2017-01

    Registered record
    Registry ID
    NCT02954978
    Conditions
    Parkinson Disease; Parkinsons Disease With Dementia
    Interventions
    Placebo Oral Capsule; Nilotinib 150mg oral capsule [Tasigna]; Nilotinib 300mg oral capsule [Tasigna]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01
    Completion
    2020-07
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Parkinsons Disease With Dementia
    InterventionPlacebo Oral Capsule; Nilotinib 150mg oral capsule [Tasigna]; Nilotinib 300mg oral capsule [Tasigna]
    PhasePhase 2
    Registry statusCompleted

  • Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line

    NCT05734053 · start 2016-06-28

    Registered record
    Registry ID
    NCT05734053
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Nilotinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-06-28
    Completion
    2022-09-08
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionNilotinib
    PhaseNot recorded
    Registry statusCompleted

  • A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

    NCT02611492 · start 2016-04

    Registered record
    Registry ID
    NCT02611492
    Conditions
    Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
    Interventions
    Nilotinib; Methotrexate; Aracytine (Ara C); Granulocyte Colony-Stimulating Factor (G-CSF); Depomedrol; Dexamethasone; Vincristine; Imatinib; 6 Mercaptopurine (6MP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-04
    Completion
    2025-12
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
    InterventionNilotinib; Methotrexate; Aracytine (Ara C); Granulocyte Colony-Stimulating Factor (G-CSF) +5 more
    PhasePhase 3
    Registry statusUnknown

  • Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

    NCT02546674 · start 2016-02-18

    Registered record
    Registry ID
    NCT02546674
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02-18
    Completion
    2021-03-25
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionNilotinib
    PhasePhase 4
    Registry statusCompleted

  • Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

    NCT02389920 · start 2015-04

    Registered record
    Registry ID
    NCT02389920
    Conditions
    Leukemia, Chronic Myeloid
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2018-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Chronic Myeloid
    InterventionNilotinib
    PhasePhase 4
    Registry statusUnknown

  • Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

    NCT02353728 · start 2015-01

    Registered record
    Registry ID
    NCT02353728
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2021-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionNilotinib
    PhasePhase 2
    Registry statusCompleted

  • Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

    NCT02281474 · start 2014-11

    Registered record
    Registry ID
    NCT02281474
    Conditions
    Parkinson's Disease; Parkinson's Disease Dementia; Diffuse Lewy Body Disease
    Interventions
    Nilotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Parkinson's Disease Dementia; Diffuse Lewy Body Disease
    InterventionNilotinib
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

    NCT01871311 · start 2014-05

    Registered record
    Registry ID
    NCT01871311
    Conditions
    Colorectal Cancer; Head and Neck Cancer
    Interventions
    Nilotinib + Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-05
    Completion
    2016-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Head and Neck Cancer
    InterventionNilotinib + Cetuximab
    PhasePhase 1
    Registry statusTerminated